Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label study of intravenous Iron Isomaltoside 1000 (Monofer) vs oral iron sulphate in NDD-CKD anemia
2009-016728-29Phase 3Completed
- Sponsor
- Pharmacosmos
- Start
- Dec 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric derisomaltose in anaemia (2 arms), sponsored by Pharmacosmos. Primary endpoint: Change in hemoglobin concentration from baseline to week 8. Started Dec 2009; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
anaemia
Beyond the preview
Go deeper on 2009-016728-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016728-29.